In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Report this profile . 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. . No two people with cancer are alike. Atlanta, GA. . Official Facebook for Takeda's Oncology Business Unit. These online resources can provide you with more information about multiple myeloma and additional information that may help address day-to-day concerns associated with your treatment. Built on a legacy foundation and . This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma. 2. Text Module. Takeda Pharmaceutical Company Limited (TAK +1.8%) announces results from two clinical trials evaluating Ninlaro (ixazomib) in multiple myeloma (MM) patients. Takeda's oral multiple myeloma drug narrowly misses in Phase III study . Cambridge, MA; Osaka, Japan: Takeda Pharmaceutical Company Limited . A cancer of the bone marrow plasma cells. Key data to be presented include: . Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ... Takeda's oral multiple myeloma drug narrowly misses in Phase III study USO-NON-0202. View job description, responsibilities and qualifications. Job in Orange - Orange County - CA California - USA , 92613. . Multiple Myeloma - Clinical Care Options Sales. Takeda Oncology's 1Point Patient Assistance Program - Myeloma Crowd About Takeda Oncology. Multiple Myeloma Researcher Forges a Career Path in Immuno-oncology head of Takeda's oncology therapeutic area unit, in a statement. Oncology Territory Manager, Multiple Myeloma, San Diego Takeda Oncology Related Content. Last year, approximately 12,410 individuals died from myeloma.